Stock-Based Compensation

6 Months Ended

Jun. 30, 2012

Stock-Based Compensation [Abstract]

STOCK-BASED COMPENSATION

NOTE 8 STOCK-BASED COMPENSATION

During the six months ended June 30, 2012, the Company granted 0.5 million restricted stock units and 0.4 million stock-settled stock appreciation rights with weighted average grant date fair values of $17.11 and $7.92, respectively.

The total stock-based compensation expense included in the Company’s consolidated statements of income and comprehensive income was as follows:

	Three Months Ended				Six Months Ended
(In thousands)	June 30, 2012		July 2, 2011		June 30, 2012		July 2, 2011
Cost of sales	$	184	$	99	$	301	$	221
Selling, general and administrative expenses		1,469		929		3,308		2,597
Research and development expense		225		123		483		352
	$	1,878	$	1,151	$	4,092	$	3,170

At June 30, 2012, the total compensation cost related to unvested stock-based awards granted to employees, officers and directors under the Company’s stock-based benefit plans that had not yet been recognized was $17.0 million (net of estimated forfeitures of $6.0 million). This future compensation expense will be amortized over a weighted-average period of 1.6 years using the straight-line attribution method. The actual compensation expense that the Company will recognize in the future related to unvested stock-based awards outstanding at June 30, 2012 will be adjusted for actual forfeitures and will be adjusted based on the Company’s determination as to the extent to which performance conditions applicable to any stock-based awards have been or will be achieved.

At June 30, 2012, 1.1 million stock options with a weighted-average exercise price of $13.37 per share, intrinsic value of $0.3 million and remaining contractual term of 1.6 years were outstanding and were exercisable. At June 30, 2012, 1.6 million stock-settled stock appreciation rights with a weighted-average base value of $11.04 per share, intrinsic value of $5.2 million and remaining contractual term of 5.0 years were outstanding, and 0.9 million stock-settled stock appreciation rights with a weighted-average base value of $7.02 per share, intrinsic value of $5.2 million and remaining contractual term of 4.1 years were exercisable.